Addex Therapeutics Ltd (ADXN)

$8.92

-0.17

(-1.87%)▲

Market is closed - opens 7 PM, 05 Jun 2024

Performance

  • $8.22
    $9.20
    $8.92
    downward going graph

    7.85%

    Downside

    Day's Volatility :10.63%

    Upside

    3.02%

    downward going graph
  • $5.00
    $27.90
    $8.92
    downward going graph

    43.95%

    Downside

    52 Weeks Volatility :82.08%

    Upside

    68.03%

    downward going graph

Returns

PeriodAddex Therapeutics Ltd
3 Months
-9.01%
6 Months
49.02%
1 Year
-29.44%
3 Years
-95.45%

Highlights

Market Capitalization
10.2M
Book Value
$0.01
Earnings Per Share (EPS)
-18.4
Profit Margin
0.0%
Operating Margin TTM
-1459.2%
Return On Assets TTM
-99.44%
Return On Equity TTM
-348.48%
Revenue TTM
1.6M
Revenue Per Share TTM
2.64
Quarterly Revenue Growth YOY
-69.3%
Gross Profit TTM
1.4M
EBITDA
-10.3M
Diluted Eps TTM
-18.4
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Sell
    10%Buy
    20%Hold
    70%Sell
Based on 10 Wall street analysts offering stock ratings for Addex Therapeutics Ltd(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
1
1
1
Hold
2
3
3
Sell
7
7
7

Company Financials

FY18Y/Y Change
Revenue
6.1M
↑ 1109.03%
Net Income
-1.7M
↓ 49.86%
Net Profit Margin
-27.21%
↑ 629.01%
FY19Y/Y Change
Revenue
2.9M
↓ 54.29%
Net Income
-15.3M
↑ 798.63%
Net Profit Margin
-534.98%
↓ 507.77%
FY20Y/Y Change
Revenue
4.1M
↑ 30.77%
Net Income
-14.6M
↓ 13.0%
Net Profit Margin
-355.92%
↑ 179.06%
FY21Y/Y Change
Revenue
3.2M
↓ 19.28%
Net Income
-16.8M
↑ 19.39%
Net Profit Margin
-526.42%
↓ 170.5%
FY22Y/Y Change
Revenue
1.4M
↓ 51.22%
Net Income
-20.8M
↑ 35.52%
Net Profit Margin
-1.5K%
↓ 936.15%
FY23Y/Y Change
Revenue
1.9M
↑ 13.39%
Net Income
-12.5M
↓ 49.26%
Net Profit Margin
-654.47%
↑ 808.1%
Q4 FY22Q/Q Change
Revenue
592.4K
↑ 44.7%
Net Income
-3.7M
↓ 11.1%
Net Profit Margin
-616.38%
↑ 386.91%
Q1 FY23Q/Q Change
Revenue
548.4K
↓ 15.45%
Net Income
-2.6M
↓ 34.08%
Net Profit Margin
-480.58%
↑ 135.8%
Q2 FY23Q/Q Change
Revenue
704.5K
↑ 25.95%
Net Income
-3.0M
↑ 11.13%
Net Profit Margin
-424.04%
↑ 56.54%
Q3 FY23Q/Q Change
Revenue
327.7K
↓ 48.05%
Net Income
-2.6M
↓ 2.17%
Net Profit Margin
-798.54%
↓ 374.5%
Q4 FY23Q/Q Change
Revenue
182.4K
↓ 53.18%
Net Income
-3.4M
↑ 9.16%
Net Profit Margin
-1.9K%
↓ 1063.19%
Q1 FY24Q/Q Change
Revenue
153.5K
↑ 0.0%
Net Income
-2.9M
↑ 0.0%
Net Profit Margin
-1.9K%
↑ 0.0%
FY18Y/Y Change
Total Assets
42.9M
↑ 1278.1%
Total Liabilities
3.0M
↑ 72.79%
FY19Y/Y Change
Total Assets
34.1M
↓ 21.76%
Total Liabilities
7.7M
↑ 152.42%
FY20Y/Y Change
Total Assets
22.9M
↓ 38.9%
Total Liabilities
6.3M
↓ 25.76%
FY21Y/Y Change
Total Assets
24.7M
↑ 11.69%
Total Liabilities
6.1M
↑ 0.69%
FY22Y/Y Change
Total Assets
8.3M
↓ 63.26%
Total Liabilities
3.4M
↓ 39.95%
FY23Y/Y Change
Total Assets
5.5M
↓ 43.95%
Total Liabilities
4.2M
↑ 3.78%
Q4 FY22Q/Q Change
Total Assets
8.3M
↓ 32.34%
Total Liabilities
3.4M
↓ 21.46%
Q1 FY23Q/Q Change
Total Assets
8.0M
↓ 11.92%
Total Liabilities
3.5M
↓ 4.33%
Q2 FY23Q/Q Change
Total Assets
10.0M
↑ 23.36%
Total Liabilities
3.2M
↓ 10.89%
Q3 FY23Q/Q Change
Total Assets
6.1M
↓ 31.79%
Total Liabilities
2.2M
↓ 23.63%
Q4 FY23Q/Q Change
Total Assets
5.5M
↓ 24.38%
Total Liabilities
4.2M
↑ 59.39%
Q1 FY24Q/Q Change
Total Assets
4.6M
↑ 0.0%
Total Liabilities
3.5M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
1.8M
↓ 182.05%
Investing Cash Flow
-57.3K
↑ 7987.66%
Financing Cash Flow
38.0M
↑ 1014.47%
FY19Y/Y Change
Operating Cash Flow
-9.8M
↓ 641.3%
Investing Cash Flow
-44.7K
↓ 23.27%
Financing Cash Flow
-478.7K
↓ 101.24%
FY20Y/Y Change
Operating Cash Flow
-13.8M
↑ 28.45%
Investing Cash Flow
-67.4K
↑ 37.36%
Financing Cash Flow
52.6K
↓ 110.01%
FY21Y/Y Change
Operating Cash Flow
-16.1M
↑ 20.73%
Investing Cash Flow
-33.2K
↓ 48.98%
Financing Cash Flow
18.0M
↑ 35251.68%
FY22Y/Y Change
Operating Cash Flow
-16.4M
↑ 11.78%
Investing Cash Flow
3.0K
↓ 109.8%
Financing Cash Flow
3.1M
↓ 81.08%
Q4 FY22Q/Q Change
Operating Cash Flow
-3.1M
↑ 14.17%
Investing Cash Flow
-9.0
↓ 100.3%
Financing Cash Flow
-168.9K
↓ 104.03%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.6M
↓ 23.19%
Investing Cash Flow
-2.7K
↑ 27566.67%
Financing Cash Flow
1.1M
↓ 708.85%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.1M
↑ 16.88%
Investing Cash Flow
-2.8K
↑ 0.0%
Financing Cash Flow
5.0M
↑ 336.0%

Technicals Summary

Sell

Neutral

Buy

Addex Therapeutics Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • J Stern & Co LLP

    10.09%

Company Information

addex therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. the company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including g-protein coupled receptors (gpcrs), receptor tyrosine kinases (rtks) and cytokine receptors, such as the tnf receptor superfamily. many such targets have been widely recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery. the company’s two lead products are: dipraglurant (adx48621), an mglur5 negative allosteric modulator, or nam, which reduced parkinson’s disease levodopa-induced dyskinesia (pd-lid) in a phase ii

Organization
Addex Therapeutics Ltd
Employees
23
CEO
Mr. Timothy Mark Dyer
Industry
Health Technology

Discover More

FAQs